Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

  • Muñoz-Hernández, Rocío
  • Gato, Sheila
  • Gil-Gómez, Antonio
  • Aller, Rocío
  • Rojas, Ángela
  • Morán, Laura
  • Gallego, Javier
  • Blázquez-López, Elena
  • Gallego-Durán, Rocío
  • Montero-Vallejo, Rocío
  • García-Fernández, Vanessa
  • Maya-Miles, Douglas
  • Rico, María Carmen
  • Cubero, Francisco Javier
  • Vaquero, Javier
  • Ampuero, Javier
  • Bañares, Rafael
  • Romero-Gómez, Manuel
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Background and Aims] Extracellular vesicles (EVs) have emerged as a potential source of circulating biomarkers in liver disease. We evaluated circulating AV+ EpCAM+ CD133+ EVs as a potential biomarker of the transition from simple steatosis to steatohepatitis., [Methods] EpCAM and CD133 liver proteins and EpCAM+ CD133+ EVs levels were analysed in 31 C57BL/6J mice fed with a chow or high fat, high cholesterol and carbohydrates diet (HFHCC) for 52 weeks. The hepatic origin of MVs was addressed using AlbCrexmT/mG mice fed a Western (WD) or Dual diet for 23 weeks. Besides, we assessed plasma MVs in 130 biopsy-proven NAFLD patients., [Results] Hepatic expression of EpCAM and CD133 and EpCAM+ CD133+ EVs increased during disease progression in HFHCC mice. GFP+ MVs were higher in AlbCrexmT/mG mice fed a WD (5.2% vs 12.1%) or a Dual diet (0.5% vs 7.3%). Most GFP+ MVs were also positive for EpCAM and CD133 (98.3% and 92.9% respectively), suggesting their hepatic origin. In 71 biopsy-proven NAFLD patients, EpCAM+ CD133+ EVs were significantly higher in those with steatohepatitis compare to those with simple steatosis (286.4 ± 61.9 vs 758.4 ± 82.3; p < 0.001). Patients with ballooning 367 ± 40.6 vs 532.0 ± 45.1; p = 0.01 and lobular inflammation (321.1 ± 74.1 vs 721.4 ± 80.1; p = 0.001), showed higher levels of these EVs. These findings were replicated in an independent cohort., [Conclusions] Circulating levels of EpCAM+ CD133+ MVs in clinical and experimental NAFLD were increased in the presence of steatohepatitis, showing high potential as a non-invasive biomarker for the evaluation and management of these patients., This work was supported by Consejería de Salud y Familias (PI-0039-2017 to RM), Sociedad Andaluza de Patología Digestiva (Beca Dr. Gonzalo Miño Fugarolas to RM), Talento Doctores (PID Junta Andalucía, DOC_00866, to RM), Consejería Economía, Conocimiento, Empresas y Universidad, Proyecto P20_01075 de financiación pública en la convocatoria 2020 en la modalidad Ayudas a proyectos de I+D+i, destinadas a las universidades y entidades públicas de investigación calificadas como agentes del Sistema Andaluz del Conocimiento, en el ámbito del Plan Andaluz de Investigación, Desarrollo e Innovación (PAIDI 2020). Convocatoria financiada con Fondo Europeo de Desarrollo Regional (FEDER) al 80%. Andalucía se mueve con Europa to MR. Instituto de Salud Carlos III to MR/RM (PI19/00589), to MR (PMP21/00078) and PI22/01342 to MR, PFIS FI20/00201 to SG, Consejería de Salud y Familias, Junta de Andalucía to AGG (RH-122-2020) and AR (RH-002-2021), i-PFIS 18/00041 to RM, Sara Borrel CD21-00095 to RGD and Comunidad de Madrid y Fondos FEDER ‘Una manera de hacer Europa’, S2017/BMD3727, ExoHep-CM to RB., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel insights into metabolic-associated steatotic liver disease preclinical models

  • Montero-Vallejo, Rocío
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Martín, Franz
  • Romero-Gómez, Manuel
  • Gallego-Durán, Rocío
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims., The research leading to these results has received funding from the Consejería de Salud de la Junta de Andalucía under grant agreement PC-0148-2016-0148 and PE-0451-2018, and from the Instituto de Salud Carlos III under grant agreements CD21/00095, PI19/01404, PI19/00589, PI22/01342, PI22/01345 and IFI18/00041 and Ministerio de Economía y Competitividad under grant agreement AGL-2017-86927-R and PID2020-116731RB-C21. Rocío Montero-Vallejo has received the Juan Manuel Herrerías from Sociedad Andaluza de Patología Digestiva, CIBERehd grants to support mobility and improve mice handling. Rocío Gallego-Durán has received the Andrew K Burroughs Fellowship from European Association for the Study of the Liver (EASL), Aprendizaje de Nuevas Tecnologías fellowship from Asociación Española para el Estudio del Hígado (AEEH) and CIBERehd Grant to support researcher's mobility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Halting hepatocellular carcinoma: Identifying intercellular crosstalk in HBV-driven disease

  • Zhou, Lingyun
  • Liu, Chang-Hai
  • Lv, Duoduo
  • Sample, Klarke Michael
  • Rojas, Ángela
  • Zhang, Yugu
  • Qiu, Huandi
  • He, Linye
  • Zheng, Li
  • Chen, Liyu
  • Cai, Binru
  • Hu, Yiguo
  • Romero-Gómez, Manuel
The raw sequencing data from this study were deposited in the Genome Sequence Archive for Human, accession numbers GSA: HRA002715, HRA004787, and HRA007976, and are publicly available as of the date of publication. Original western blot images and microscopy data reported in this paper have been deposited at Mendeley at https://doi.org/10.17632/hx8g373hpt.1 and are publicly available as of the date of publication. Tools for HBV expression and genome distribution analysis from scRNA-seq data have been deposited on GitHub at https://github.com/Lingyun-Zhou/HBV_scRNAseq and are publicly available as of the date of publication. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request., Hepatitis B infection can lead to liver fibrosis and hepatocellular carcinoma (HCC). Despite antiviral therapies, some patients still develop HCC. This study investigates hepatitis B virus (HBV)-induced hepatocyte-hepatic stellate cell (HSC) crosstalk and its role in liver fibrosis and HCC. Using MYC-driven liver cancer stem cell organoids, HCC-patient-derived xenograft (PDX) models, and HBV replication models, this study reveals that HBV transcription affected hepatocyte development, activated the DNA repair pathway, and promoted glycolysis. HBV activated nicotinamide phosphoribosyltransferase (NAMPT) through DNA damage receptor ATR. NAMPT-insulin receptor (INSR)-mediated hepatocyte-HSC crosstalk caused HSCs to develop a myofibroblast phenotype and activated telomere maintenance mechanisms via PARP1 multisite lactylation. Inhibition of the ATR-NAMPT-INSR-PARP1 pathway effectively blocks HBV-induced liver fibrosis and HCC progression. Targeting this pathway could be a promising strategy for chronic HBV infection management., We would specifically like to thank the West China Hospital Biological Sample Bank. The graphic abstract was created in BioRender (L. Zhou, https://BioRender.com/n31r784). This work was financially supported and sponsored by National Natural Science Foundation of China 81802468 (L. Zhou), Science and Technological Supports Project of Sichuan Province 2023YFS0088 (L. Zhou), Innovate Health Initiative GRIPonMASH project 101132946 (M.R.-G.), Instituto de Salud Carlos III PI22/01342 (M.R.-G.), and Comprehensive AIDS Prevention and Control Research Platform of West China Hospital, Sichuan University 0040204151013 (L.C.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis

  • Romero-Gómez, Manuel
  • Ferretti, Sebastián
  • Arab, Juan Pablo
[EN] The proposal for a nomenclature changes stems from the inaccuracy of the original term, as well as on the absence of any allusion to metabolic disorders and the stigma generated by the use of the terms “nonalcoholic” and “fatty”. The term thus proposed a change from basing its definition on the existence of a histological lesion typical of alcohol damage in the absence of significant alcohol consumption to being defined by the presence of hepatic steatosis demonstrated through biopsy or imaging methods associated with cardiometabolic risk factors, such as diabetes, obesity, arterial hypertension or dyslipidemia in the absence of pathological alcohol consumption. This change has made it possible to define hepatic steatosis as a disease attributed to metabolic disorder and alcohol. This proves the specific similarities and differences between metabolic hepatic steatosis and alcoholic hepatic steatosis, both in their pathogenesis and in the role of genetics and the intestine-liver axis, as well as in potential therapeutic options such as resmetirom or semaglutide. Likewise, this change has made it possible to classify other specific and rare causes of hepatic steatosis, such as hepatotoxicity, immunogenic diseases, hepatitis C or celiac disease., [ES] La propuesta de cambio de nomenclatura encontraba su razón de ser en la inexactitud del término original, así como en la ausencia de alusión a los trastornos metabólicos que conforman su esencia y al estigma que genera el uso tanto del término «no alcohólico», como del de «graso» (fatty en inglés o gordura en portugués). El término pasó de basar su definición en la existencia de una lesión histológica típica del daño por alcohol en ausencia de consumo significativo a definirse a partir de la presencia de esteatosis hepática demostrada por biopsia o métodos de imagen asociados a factores de riesgo cardiometabólicos, como la diabetes, la obesidad, la hipertensión arterial o la dislipemia en ausencia de consumo patológico de alcohol. Este cambio de la nomenclatura ha permitido definir una nueva entidad, la esteatosis hepática por trastorno metabólico y alcohol (EHmet-ALD) que muestra similitudes y diferencias específicas tanto con la esteatosis hepática metabólica (EHmet) como con la esteatosis hepática alcohólica (EHalc) tanto en la patogenia como en el papel de la genética y el eje intestino-hígado como en las potenciales opciones terapéuticas como resmetirom o semaglutida. De la misma forma, este cambio ha permitido ordenar otras causas específicas y poco frecuentes de esteatosis hepática como la hepatotoxicidad, enfermedades monogénicas, la hepatitis C o la enfermedad celíaca., With thanks to the Research Project PI2201342., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease

  • Priego-Parra, Bryan Adrián
  • Gallego-Durán, Rocío
  • Román-Calleja, Berenice M.
  • Velarde-Ruiz Velasco, José Antonio
  • Romero-Gómez, Manuel
  • Gracia-Sancho, Jordi
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a pressing global health concern. The complexity of MASLD and the lack of universally effective treatments expose the limitations of current interventions, which focus mainly on lifestyle modifications. Here, we explore the multilayered nature of MASLD, emphasizing its pathophysiology in shaping future medical and lifestyle interventions from a personalized medicine perspective, based on individual molecular profiles. Additionally, we address the limitations of current animal models in reflecting human metabolic syndrome and sex-specific differences. We argue that a holistic approach, integrating social determinants of health, patient preferences, and adherence patterns, is essential for advancing MASLD management effectively., Authors acknowledge continuous funding from the Instituto de Salud Carlos III (ISCIII; currently PI23/00945, DTS22/00010 & DTS24/00035 to J.G.-S., CD21/00095, PI22/01342, PI22/01345 and PI24/02008 to R.G.-D. and M.R.-G., all co-funded by the European Union), the AGAUR-Generalitat de Catalunya (2021 SGR 01322 & 2021 PROD 00036) to J.G.-S and the CIBEREHD. CIBEREHD is funded by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Highlighting the relevance of a multidisciplinary approach in metabolic-asociated steatotic liver disease (MASLD)

  • Lara-Romero, Carmen
  • Fernández-Gómez, Miguel Angel
  • Martín, Franz
  • Castilla Guerra, Luis
  • Funuyet-Salas, Jesús
  • Berná, Genoveva
  • Millán Domínguez, Raquel
  • Romero-Gómez, Manuel
[Introduction] Metabolic-associated steatotic liver disease (MASLD) represents a prevalent and multifaceted systemic condition, characterized by its intricate interplay of obesity, type 2 diabetes, and various metabolic perturbations. Given its complexity, MASLD necessitates a comprehensive multidisciplinary strategy for both prevention and management., [Areas covered] Each of the experts who contributed to this review has made an in-depth review of the literature within their field of knowledge using PubMed. This review covers nutrition, physical activity and exercise, type 2 diabetes mellitus, cardiovascular risk factors, psychological approach, and clinical care by hepatologists in MASLD patients., [Expert opinion] Adherence to the Mediterranean diet and engagement in exercise have been shown to ameliorate and potentially reverse MASLD. The hepatologist plays a pivotal role in diagnosis, assessment of liver comorbidities, and disease staging, emphasizing lifestyle modification and tailored therapy. Nutritionists are vital in dietary interventions, while specialists in sports medicine are essential for overcoming sedentary lifestyles, requiring fitness evaluations to customize exercise prescriptions. Psychological support addresses social and adherence challenges, enhancing patient management. Additionally, metabolic medicine experts are crucial for managing associated comorbidities, including cardiovascular risk factors and type 2 diabetes., This study was supported by the Instituto de Salud Carlos III through the research grant PI22/01342, corresponding to the MERGE Project: Combinatorial therapies analysis for the amelioration of Non-alcoholic Fatty Liver Disease. The authors gratefully acknowledge this funding, which made the development and completion of this work possible., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mechanistic insights into the liver-brain axis during chronic liver disease

  • Siddle, Matthew
  • Gallego-Durán, Rocío
  • Goel, Deepika
  • Renquist, Benjamin J.
  • Holt, Marie K.
  • Hadjihambi, Anna
The liver is a metabolically flexible tissue, adapting its functions to changes in nutrient availability and physiological states. This adaptability is crucial for maintaining metabolic homeostasis and likely involves communication with the central nervous system through the liver–brain axis. The liver also receives a constant influx of nutrients, hormones and microbial metabolites from the gastrointestinal tract in a multifaceted communication network, the gut–liver–brain axis. Dysregulation of this communication can lead to hepatic encephalopathy and cognitive impairments in early-stage chronic liver disease, such as metabolic dysfunction-associated steatotic liver disease, substantially affecting patient quality of life. This Review examines key signalling pathways along the liver–brain axis: humoral signalling, including metabolites, hepatokines, toxins and inflammation, and neural pathways, focusing on afferent signalling through the common hepatic branch of the vagus nerve. We discuss how each pathway might contribute to behavioural and mood changes in chronic liver disease and the development of hepatic encephalopathy. Although the humoral effects have been studied more extensively, we propose that the afferent vagus nerve is central to liver disease-associated cognitive and behavioural complications. Finally, we highlight how new techniques and tools could advance our understanding of the gut–liver–brain communication that affects behaviour., M.S. is funded by the Wellcome Trust as part of the Neuro-Immune Interactions in Health & Disease Wellcome Trust PhD Programme (218452/Z/19/Z). R.G.D. acknowledges support to ISCIII from grants CD21/00095, PI22/01342, PI19/01404, PI24/02008. B.J.R. is funded by the NIH (NIDDK R01DK132281) and the US Department of Defense (W81XWH-22-2-0043 and PR221455 HT9425-23-1-0810). M.K.H. is funded by the British Heart Foundation (FS/IPBSRF/20/27001) and the Royal Society (RG\R1\241213). A.H. is funded by UKRI, Future Leaders Fellowship (MR/X033287/1) and the Foundation for Liver Research., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deciphering the role of ammonia in MASLD: From a neurotoxin to a metabolic by-product, Descifrando el papel del amoníaco en el MASLD: de neurotoxina a subproducto metabólico

  • Zurita-Palomo, Carola
  • Martín, Franz
  • Maya-Miles, Douglas
  • Ampuero, Javier
  • Romero-Gómez, Manuel
  • Gallego-Durán, Rocío
Ammonia, a nitrogen-containing compound produced during amino acid catabolism, plays a key role in nitrogen homeostasis. The primary source of ammonia in humans is the gut, where it is produced from dietary sources, luminal bacterial urease activity and glutamine deamination in enterocytes.1 This gut-derived ammonia is transported to the liver via the portal vein, and because ammonia is potentially neurotoxic, rapid and efficient removal is essential. Among others organs, the liver is the main organ responsible for its detoxification via the urea cycle. Ureagenesis occurs specifically in periportal hepatocytes by the action of urea cycle enzymes (UCEs), which involves two mitochondrial enzymes (carbamoyl phosphate synthetase 1 (CPS1) and ornithine transcarbamylase (OTC)) and three cytosolic enzymes (arginosuccinate synthetase (ASS), arginosuccinate lyase (ASL) and arginase 1 (ARG1)). In health, ammonia is converted into urea, which is excreted by the kidneys maintaining the systemic nitrogen balance, The research leading to these results has received funding from Instituto de Salud Carlos III under grant agreements PI24/02008, PI22/01342, from Agencia Estatal de Investigación under grant agreement PID2024-162275OB-I00 and European Partnership for Personalized Medicine under grant agreement EPPERMED2024-496. RGD and DMM are both recipients of EMERGIA fellowships from Consejería de Universidad, Investigación e Innovación from Junta de Andalucía under grant agreements DGP_EMEC_2023_00394 and DGP_EMEC_2023_00472, Peer reviewed